If Elevance Health (ELV) is on your watchlist, you might be wondering why its shares have slipped this year and whether now offers a window to reconsider your stance. The latest movement is not tied to a particular news event, but it has been enough to catch investors’ attention and stir questions about what the market is signaling for this leading health insurer. In times like these, a valuation reset or an overreaction can create opportunity or signal deeper shifts in sentiment.
Looking at the bigger picture, Elevance Health’s share price has lost ground this year, with a decline over the past three months extending a downward stretch that began at the start of the year. Longer-term investors who held the stock for five years still see modest growth, but three-year and one-year total returns are both in negative territory, suggesting recent momentum is firmly on the back foot. Meanwhile, annual revenue and profit growth remain positive, which adds another layer to the puzzle for anyone weighing future prospects.
So, with revenue and earnings trending up while the stock price lags, is Elevance Health undervalued right now, or is the market already pricing in everything we know about its future growth?
According to the most popular narrative, Elevance Health is currently trading at a significant discount compared to its estimated fair value. This suggests the stock may be undervalued and could present an opportunity for strategic investors.
“As a potential growth investment, Elevance Health offers a compelling mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience.”
Curious about what is fueling that undervaluation? The narrative highlights a blend of surprisingly robust earnings growth, margin recoveries, and sector-specific catalysts that could reshape expectations. Interested in the factors behind this bullish fair value? Learn more about the standout elements and projections supporting this perspective.
Result: Fair Value of $390.54 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent cost inflation and ongoing Medicaid enrollment declines could undermine the undervaluation thesis if these headwinds continue into the next year.
Find out about the key risks to this Elevance Health narrative.
Taking a different approach, our DCF model also points to Elevance Health being undervalued. This method analyzes the company’s future cash flows and offers another lens on its potential. Does this add conviction or more questions?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Elevance Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
If you see things differently or want to investigate Elevance Health on your own terms, you can craft your own narrative in just a few minutes: Do it your way.
A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Elevance Health.
Smart investors always keep their options open. Broaden your search and get ahead of the next trend with these expert-curated investment themes, all waiting for your attention now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ELV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
link